230 related articles for article (PubMed ID: 22429766)
1. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Sutcliffe S; Grubb Iii RL; Platz EA; Ragard LR; Riley TL; Kazin SS; Hayes RB; Hsing AW; Andriole GL;
BJU Int; 2012 Oct; 110(7):1050-9. PubMed ID: 22429766
[TBL] [Abstract][Full Text] [Related]
2. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
[TBL] [Abstract][Full Text] [Related]
3. Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
BJU Int; 2012 Oct; 110(7):1023-9. PubMed ID: 22233355
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
5. Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial.
Johnson CC; Hayes RB; Schoen RE; Gunter MJ; Huang WY;
Am J Gastroenterol; 2010 Dec; 105(12):2646-55. PubMed ID: 20808298
[TBL] [Abstract][Full Text] [Related]
6. Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.
Carballido J; Fourcade R; Pagliarulo A; Brenes F; Boye A; Sessa A; Gilson M; Castro R
Int J Clin Pract; 2011 Sep; 65(9):989-96. PubMed ID: 21733048
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of BPH and lower urinary tract symptoms in West Africans.
Chokkalingam AP; Yeboah ED; Demarzo A; Netto G; Yu K; Biritwum RB; Tettey Y; Adjei A; Jadallah S; Li Y; Chu LW; Chia D; Niwa S; Partin A; Thompson IM; Roehrborn C; Hoover RN; Hsing AW
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):170-6. PubMed ID: 21912428
[TBL] [Abstract][Full Text] [Related]
8. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
9. Physical activity and benign prostatic hyperplasia-related outcomes and nocturia.
Wolin KY; Grubb RL; Pakpahan R; Ragard L; Mabie J; Andriole GL; Sutcliffe S
Med Sci Sports Exerc; 2015 Mar; 47(3):581-92. PubMed ID: 25010403
[TBL] [Abstract][Full Text] [Related]
10. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
11. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
12. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
[TBL] [Abstract][Full Text] [Related]
13. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
[TBL] [Abstract][Full Text] [Related]
14. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.
Sarma AV; Burke JP; Jacobson DJ; McGree ME; St Sauver J; Girman CJ; Lieber MM; Herman W; Macoska J; Montie JE; Jacobsen SJ
Diabetes Care; 2008 Mar; 31(3):476-82. PubMed ID: 18071006
[TBL] [Abstract][Full Text] [Related]
15. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
16. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
Hernández C; Estivill E; Prieto M; Badía X
Curr Med Res Opin; 2008 Apr; 24(4):1033-8. PubMed ID: 18302812
[TBL] [Abstract][Full Text] [Related]
17. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
MacDonald R; Tacklind JW; Rutks I; Wilt TJ
BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
[TBL] [Abstract][Full Text] [Related]
18. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.
Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J
Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091
[TBL] [Abstract][Full Text] [Related]
20. Rising PSA in patients with minor LUTS without evidence of prostatic carcinoma: a missing link?
van Renterghem K; Van Koeveringe G; Van Kerrebroeck P
Int Urol Nephrol; 2007; 39(4):1107-13. PubMed ID: 17602307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]